CRISPR Therapeutics Q3 EPS $(1.41) Beats $(1.96) Estimate
Portfolio Pulse from Benzinga Newsdesk
CRISPR Therapeutics reported Q3 losses of $(1.41) per share, beating the analyst consensus estimate of $(1.96) by 28.06 percent. This represents a 37.05 percent increase over losses of $(2.24) per share from the same period last year.
November 06, 2023 | 10:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CRISPR Therapeutics reported better than expected Q3 losses, which could positively impact the stock in the short term.
CRISPR Therapeutics reported Q3 losses that were less than expected, which is generally seen as positive news by investors. This could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100